Theralase Technologies Inc.

Theralase Technologies Inc.

TLTFF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$33M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Theralase Technologies Inc.Theralase Technologies Inc.-13--55%--
$-0.05

Current Fair Value

140.3% downside

Overvalued by 140.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$33.00 Million
Enterprise Value$27.89 Million
Earnings per Share$-0.02
Beta0.59
Outstanding Shares284,016,013

Return

Return on Equity-55.41%ROE
Return on Assets-46.66%
Return on Invested Capital-54.97%

Valuation & Multiples

P/E Ratio-13.03P/E Ratio
PEG-112.59PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue34.76
Enterprise Value to EBIT-7.38
Enterprise Value to Net Income-8
Total Debt to Enterprise0.01
Debt to Equity0.02Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 19, 2026
EPS Estimate
-$0.00
Consensus analyst estimate
Revenue Estimate
$146,781
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Theralase Technologies Inc.

14 employees
CEO: Roger J. Dumoulin-White

Theralase Technologies Inc., founded in Toronto, Canada in 1994, is a clinical-stage pharmaceutical company focused on the development of innovative therapies and medical devices. The company's pharmaceutical division specializes in the ...

Questions & Answers